Video Shorts

0:44
Exploring ctDNA Dynamics in the IMvigor011 Trial
7 months ago
by
Thomas Powles, MD, MBBS, MRCP

0:53
Unpacking the Final Data From SunRISe-2
7 months ago
by
Andrea Necchi, MD

0:46
Top ASCO GU 2026 Abstracts According to Fellows
7 months ago
by
Riley Kandel

0:45
Imaging Modalities for Metastatic Breast Cancer Diagnosis and Staging
7 months ago
by
Igor Makhlin, MD

1:30
Rising Stars in GU Oncology Share New Data at OncLive Fellows Forum
7 months ago
by
Riley Kandel

1:25
Examining Alternative Splicing in Metastatic Bladder Cancer
7 months ago
by
Arshed Al-Obeidi, MD

0:52
Sarcomatoid vs Rhabdoid Dedifferentiation Outcomes in mccRCC
7 months ago
by
Akshit Chitkara, MD

0:57
The Exploration of Golcadomide in LBCL Management
7 months ago
by
Jason Westin, MD

0:59
Important Upcoming Clinical Trials to Watch For in MCL
7 months ago
by
Tycel Phillips, MD

0:57
Subcutaneous Blinatumomab Demonstrates Promising Efficacy and Safety in First Patient With MPAL
7 months ago
by
Ashkan Emadi, MD, PhD

2:36
Real-World Data for Luspatercept in Lower-Risk MDS
7 months ago
by
Amer Zeidan, MBBS, MD

0:47
Implications of the Negative VERONA Trial of Venetoclax/Azacitidine in Higher-Risk MDS
7 months ago
by
Guillermo Garcia-Manero, MD

0:41
First TTFields Approval in Pancreatic Cancer Paves Way for More Multimodal Approaches
7 months ago
by
Vincent J. Picozzi, MD

1:46
Understanding the Therapeutic Team Delivery Concept in Oncology
7 months ago
by
Maurie Markman, MD

0:59
Reexamining the Definition of Postpartum Breast Cancer
7 months ago
by
Lisa Zhang, MD

3:41
OncLive News Roundup for the Week of 2/15
7 months ago
by
Courtney Flaherty(+1 more)

1:35
Evolving Frontline Treatment Options in EGFR-Mutated NSCLC
7 months ago
by
Joel Neal, MD, PhD

1:41
Expert Insight on FDA Approval of T-DXd Plus Pertuzumab in HER2+ Breast Cancer
7 months ago
by
Riley Kandel

1:10
The Evaluation of CELMoDs in Multiple Myeloma
7 months ago
by
Sagar Lonial, MD, FACP, FASCO

0:49
Highlighting the Potential Implications of the Ongoing INAVO123 Trial in HR+ Breast Cancer
7 months ago
by
Reva K. Basho, MD

0:59
STELLAR-303 Paves the Way for Potential FDA Approval of Immunotherapy-Based Regimen in MSS CRC
7 months ago
by
Anwaar Saeed, MD

1:32
Deconstructing Clinical Trial Interpretation for Fellows
7 months ago
by
Matthew Hadfield, DO

0:23
Starving Breast Cancer of Copper to Stop Disease From Spreading
7 months ago
by
Linda Vahdat, MD, MBA

0:25
Highlighting the Role of Pathologists in Breast Cancer Care
7 months ago
by
David L. Rimm, MD, PhD

0:31
The Importance of Patient Selection for Breast Cancer Treatment Optimization
7 months ago
by
Vikram C. Gorantla, MD

1:10
Boosting Gender Equity in the Oncology Workforce
7 months ago
by
Ana Velázquez Mañana, MD, MSc, FASCO

1:42
Tracing the Evolution of Multidisciplinary Cancer Care
7 months ago
by
Maurie Markman, MD

1:10
Go Behind-the-Scenes With OncLive at TCT 2026
7 months ago
by
Courtney Flaherty

0:44
Reducing Time to Breast Cancer Screening and Diagnosis
7 months ago
by
Martha Welman, MD

0:41
Exploring the Significance of a Pembrolizumab-Based Regimen in Ovarian Cancer
7 months ago
by
Emese Zsiros, MD, PhD
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Living Guideline for Systemic Treatment of Recurrent Ovarian Cancer
2
OSE2101 Plus Pembrolizumab as Maintenance Boosts PFS in Platinum-Sensitive Ovarian Cancer
3
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
4
The OncFive: Top Oncology Articles for the Week of 9/14/2026
5
